Similar articles for PMID: 30375760

Year	Number of Results
2000	1
2001	1
2002	3
2003	2
2004	1
2006	2
2007	2
2008	3
2009	3
2010	2
2011	1
2012	3
2013	6
2014	6
2015	11
2016	9
2017	10
2018	5
2019	11
2022	1
2024	0

1

Real-World Effectiveness of Disease-Modifying Therapies in Korean Patients with Relapsing Multiple Sclerosis.

Kim SH, Park MS, Kim W, Huh SY, Shin HJ, Hyun JW, Kim HJ. Kim SH, et al. J Clin Neurol. 2019 Jan;15(1):20-26. doi: 10.3988/jcn.2019.15.1.20. Epub 2018 Oct 26. J Clin Neurol. 2019. PMID: 30375760 Free PMC article.

2

Teriflunomide for multiple sclerosis.

He D, Zhang C, Zhao X, Zhang Y, Dai Q, Li Y, Chu L. He D, et al. Cochrane Database Syst Rev. 2016 Mar 22;3(3):CD009882. doi: 10.1002/14651858.CD009882.pub3. Cochrane Database Syst Rev. 2016. PMID: 27003123 Free PMC article. Review.

3

Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.

Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G. Filippini G, et al. Cochrane Database Syst Rev. 2017 Apr 25;4(4):CD012200. doi: 10.1002/14651858.CD012200.pub2. Cochrane Database Syst Rev. 2017. PMID: 28440858 Free PMC article. Review.

4

Teriflunomide for multiple sclerosis.

He D, Xu Z, Dong S, Zhang H, Zhou H, Wang L, Zhang S. He D, et al. Cochrane Database Syst Rev. 2012 Dec 12;12:CD009882. doi: 10.1002/14651858.CD009882.pub2. Cochrane Database Syst Rev. 2012. PMID: 23235682 Updated. Review.

5

Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.

La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A. La Mantia L, et al. Cochrane Database Syst Rev. 2016 Nov 24;11(11):CD009333. doi: 10.1002/14651858.CD009333.pub3. Cochrane Database Syst Rev. 2016. PMID: 27880972 Free PMC article. Review.

6

Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.

Goldberg LD, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM. Goldberg LD, et al. J Manag Care Pharm. 2009 Sep;15(7):543-55. doi: 10.18553/jmcp.2009.15.7.543. J Manag Care Pharm. 2009. PMID: 19739877 Free PMC article.

7

Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.

La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A. La Mantia L, et al. Cochrane Database Syst Rev. 2014 Jul 26;(7):CD009333. doi: 10.1002/14651858.CD009333.pub2. Cochrane Database Syst Rev. 2014. PMID: 25062935 Updated. Review.

8

Dimethyl fumarate for multiple sclerosis.

Xu Z, Zhang F, Sun F, Gu K, Dong S, He D. Xu Z, et al. Cochrane Database Syst Rev. 2015 Apr 22;2015(4):CD011076. doi: 10.1002/14651858.CD011076.pub2. Cochrane Database Syst Rev. 2015. PMID: 25900414 Free PMC article. Review.

9

Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis.

Fogarty E, Schmitz S, Tubridy N, Walsh C, Barry M. Fogarty E, et al. Mult Scler Relat Disord. 2016 Sep;9:23-30. doi: 10.1016/j.msard.2016.06.001. Epub 2016 Jun 8. Mult Scler Relat Disord. 2016. PMID: 27645339 Review.

10

Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients.

Romeo M, Martinelli-Boneschi F, Rodegher M, Esposito F, Martinelli V, Comi G; San Raffaele Multiple Sclerosis Clinical Group. Romeo M, et al. Eur J Neurol. 2013 Jul;20(7):1060-7. doi: 10.1111/ene.12119. Epub 2013 Feb 20. Eur J Neurol. 2013. PMID: 23425504

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

75 results

Results by year